| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.033 | 0.6 |